[Edaily Reporter Lee So-Hyun ] SKTelecom(017670)SK Group is investing approximately 3971억 won in #SK hynix’s U.S. NAND business subsidiary. This move is seen as an effort to strengthen semiconductor collaboration within the SK Group to secure synergies with its artificial intelligence (AI) business.
SK Group Chairman Choi Tae-won announces the investment plan on the 29th at the Blue House during a public briefing on the three major megaprojects presided over by President Lee Jae-myung. (Photo: Blue House Press Corps)
SKTelecom announced on the 29th that it will acquire 642 shares of its U.S. subsidiary, “SK hynix NAND Product Solutions Corp.,” for 3971억2904만7957원.
The acquisition amount represents 3.07% of SKTelecom’s equity capital of 12조9552억9239만원. Following the acquisition, SKTelecom’s stake will be 0.62%. The acquisition will be made via a cash investment, and the scheduled completion date is the 23rd of next month.
Regarding the purpose of the acquisition, SKTelecom explained, “We are pursuing the acquisition of a stake in SK hynix NAND Product Solutions Corp. to secure synergies with our AI business.”
This disclosure marks the first capital contribution under the capital contribution agreement announced by SKTelecom on the 25th. SKTelecom had previously announced that it had entered into a capital contribution agreement to acquire new shares in the company. This acquisition of new shares is the first capital contribution made in response to the company’s request for capital payment.
SK hynix NAND Product Solutions Corp. is a U.S.-based affiliate of SK hynix, with semiconductor sales and research and development as its core businesses. Based on this year’s financial statements, its total assets amount to 7조6967억원, revenue to 9조298억원, and net income to 7364억원. Its total equity stands at minus 9088억원.
The biggest bottleneck for AI servers is memory. As the KV cache—where large language models (LLMs) store past computations—accumulates, the required memory capacity increases exponentially. This prob…
Concerns about “tax risks” have been raised in some quarters of the financial investment, pharmaceutical, and biotech markets regarding Genosco, a subsidiary of OSCOTEC Inc.(039200)specializing in new…
As July began (June 29–July 3), the pharmaceutical and biotech industries turned their attention to Celltrion Pharm Inc.’s large-scale investment in production facilities and AriBio’s successful fundr…
